HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND THEIR APPLICATION Russian patent published in 2021 - IPC C07D413/04 C07D413/14 C07D403/04 C07D417/04 C07D401/04 C07D417/14 C07D487/08 C07D491/08 C07D498/08 A61K31/4184 A61K31/5377 A61P19/00 A61P25/00 A61P35/00 

FIELD: chemistry.

SUBSTANCE: present invention relates to a compound of formula I

or its pharmaceutically acceptable salt. According to formula I, is pyrrolidinone, oxazolidinone, imidazolidinone, dihydrotriazolone, piperidinone, tetrahydropyrimidinone, morpholinone, oxazinanone, piperazinone, thiomorpholinone, thiazinane dioxide, pyridinone, pyridazinone, oxazepanone, diazepanone, diazabicyclo[3.1.1]heptanone, diazabicyclo[3.2.1]octanone, diazabicyclo[3.2.2]nonanone or oxaazabicyclo[3.2.1]octanone where each ring represented by contains an alpha carbonyl with respect to the nitrogen atom that connects the ring to the backbone to form a cyclic amide; ring X is phenyl, a 5-6 membered monocyclic heteroaryl ring containing 1-4 heteroatoms independently selected from nitrogen and oxygen, fused with a 9-10 membered heterocyclic ring containing 1-3 heteroatoms independently selected from nitrogen and oxygen, or a condensed 9-10 membered heteroaryl ring containing 1-3 heteroatoms independently selected from nitrogen and sulfur; Z is N or CH; the values ​​of R^a, R¹, R², R³, R⁴ and p are as defined in the claims. Also provided are a pharmaceutical composition, a method for inhibiting IRAK and a method for treating an IRAK-mediated disorder.

EFFECT: proposed compounds display inhibitory activity against IRAK and can be used for the treatment of IRAK-mediated disorders.

11 cl, 2 tbl, 234 ex